Novo's CagriSema leads to 25% weight loss in women
FROM THE WIRE · SEEKINGALPHA.COM
Novo Nordisk’s CagriSema phase 3 data shows ~25% weight loss at 68 weeks across menopausal groups. Read more here.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive phase 3 obesity drug data is relevant for the pharmaceutical sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01CagriSema phase 3 data shows about 25% weight loss at 68 weeks.
- 02The results cover menopausal female groups.
- 03The item provides no further financial details.